BusinessAvid Bioservices and Oncologie Enter Into Asset Assignment and Purchase Agreement for Avid’s PS-Targeting Program Including BavituximabBy Nasdaq OMXFeb 12, 2018, 1:05 PM UTC
BusinessPeregrine Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Trial Evaluating Bavituximab Treatment Combination in Patients with Newly Diagnosed GlioblastomaBy Nasdaq OMXSep 7, 2017, 12:10 PM UTC
BusinessPeregrine to Report Financial Results for First Quarter of Fiscal Year 2018 After Market Close on September 11, 2017By Nasdaq OMXSep 6, 2017, 8:05 PM UTC
BusinessPeregrine Pharmaceuticals Reports Financial Results for Quarter and Fiscal Year Ended April 30, 2017 and Recent DevelopmentsBy Nasdaq OMXJul 14, 2017, 8:13 PM UTC
BusinessPeregrine to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2017 After Market Close on July 14, 2017By Nasdaq OMXJul 7, 2017, 8:05 PM UTC
BusinessPeregrine Pharmaceuticals Highlights Clinical Data Presentation at AACR 2017 Annual Meeting Supporting Potential of Bavituximab to Enhance Anti-tumor Activity of ImmunotherapyBy Nasdaq OMXApr 4, 2017, 12:05 PM UTC
BusinessPeregrine Pharmaceuticals Announces Presentation of Preclinical Study Results Highlighting Potential of PS-Targeting Antibodies to Enhance Anti-Tumor Activity of Adoptive T Cell Transfer Therapy with No Added Off-Target ToxicitiesBy Nasdaq OMXApr 3, 2017, 12:05 PM UTC
BusinessPeregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2017 and Recent DevelopmentsBy Nasdaq OMXMar 13, 2017, 8:05 PM UTC
